The performance of companies tied to flagship drugs like Viagra presents a nuanced investment landscape . While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial profits , the patent expiration in key regions has introduced considerable uncertainty . Investors are now facing the effect of lower-cost